ERBB2 and metastatic colorectal cancer: Similarly, in metastatic colorectal cancer, biomarker testing for KRAS/NRAS, BRAF V600E, MSI, HER2, and NTRK fusions is essential for selecting systemic therapy and clinical trials [2,46].